Healthcare / BiotechnologyNasdaqCM
$2.81
+0.13 (+4.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.6M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-67.2%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-10.8M · FCF $-10.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | — | — | $16.0M | — | — | $0.00 | $12059.00 | $2.7M | $1.7M | $407518.00 | $669259.00 | $0.00 | — |
| Net Income | $-10.8M | $-10.8M | $3.6M | $-12.5M | $-13.6M | $-13.8M | $-6.9M | $-7.1M | $-10.8M | $-13.2M | $-13.3M | $-8.4M | $-1.6M |
| EBITDA | $-12.1M | $-12.1M | $5.7M | $-12.4M | $-13.6M | $-14.2M | $-6.8M | — | $-10.8M | — | — | — | — |
| EPS | — | — | 0.87 | -24.25 | -166.95 | -514.08 | -536.40 | — | — | — | — | — | — |
| Operating Margin | — | — | 34.9% | — | — | — | -56960.5% | — | -656.3% | — | — | — | — |
| Net Margin | — | — | 22.5% | — | — | — | -56901.7% | -264.2% | -654.2% | -3243.5% | -1993.8% | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.02 | 0.02 | 0.00 | 0.02 | 0.01 | — | 0.03 | 0.00 | — | — | — | — | — |
| Current Ratio | 6.68 | 6.68 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-10.1M | $-10.1M | $8.6M | $-9.6M | $-10.4M | $-10.7M | $-7.3M | $-8.2M | $-10.9M | $-6.5M | $-8.4M | — | — |
| Returns | |||||||||||||
| ROE | -67.2% | -67.2% | 14.0% | -204.8% | -119.1% | -94.5% | -70.5% | -107.2% | -121.0% | 686.0% | 4050.6% | -137.8% | 3.3% |
| Valuation | |||||||||||||
| P/E | — | — | 4.17 | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | 1.97 | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.65 | 0.65 | 0.58 | 0.43 | 0.24 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | — | — | — | — | — | -100.0% | -99.6% | 62.5% | 305.5% | -39.1% | — | — | — |
| EPS Growth | — | — | 103.6% | 85.5% | — | 4.2% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.87 → n/d
Residual
-5.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.